Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena finishes recruitment in obesity study
The trial is evaluating a 20 mg daily dose (10 mg dosed twice daily) of lorcaserin versus placebo over a two-year treatment period in obese patients with or
The trial is evaluating a 20 mg daily dose (10 mg dosed twice daily) of lorcaserin versus placebo over a two-year treatment period in obese patients with or
“Currently available second-line chemotherapy has very limited expectations of benefit. This clinical trial explores another treatment option for these patients,” said John Ruckdeschel, Karmanos Cancer Institute, and a
The discovery was made after the scientist Katherine Schaefer made a mistake in the laboratory and her cultured cells died. The cells that had been cultured were cancerous
Results, which demonstrated that the drug PD-02 is safe and well-tolerated, will allow Avicena to proceed with patient enrollment in a phase III Parkinson’s disease study. The FDA
Results from the first low dose trial indicate a good safety profile as well as positive immune responses in human volunteers receiving 1/10th dose of GeoVax's AIDS vaccine.
In the study there was no difference in the reduction of preterm birth incidence in patients with a previous preterm birth earlier than 35 weeks and treated with
The trials were conducted in North America by the Huntington Study Group (HSG) and in Europe in conjunction with the European HD Network (EHDN). The company expects to
A court in Beijing rejected Pfizer's request to block a Chinese drug company from using the name “Wei Ge” for one of its products. Pfizer said “Wei Ge,”
The compound, SCV-07, has potential ability to fight viral infectious diseases and has demonstrated immunomodulatory activity by increasing T-cell differentiation and function, biological processes that are necessary for
The agreement grants UCB non-exclusive rights to research and develop antibodies for an undisclosed number of targets. In return, BioWa will receive license fees, milestone payments and royalties